NCT00058487: Epirubicin and Thalidomide in Treating Patients With Liver Cancer |
|
|
| Completed | 2 | 12 | US | epirubicin hydrochloride, thalidomide | Dana-Farber Cancer Institute, National Cancer Institute (NCI) | Liver Cancer | | 01/07 | | |
NCT00820053: A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection |
|
|
| Completed | 2 | 450 | RoW | epirubicin and lipiodol, transarterial chemoembolization | Eastern Hepatobiliary Surgery Hospital | Hepatocellular Carcinoma | 12/09 | 12/10 | | |
NCT00021047: Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor |
|
|
| Completed | 1/2 | | US | capecitabine, carboplatin, epirubicin hydrochloride | National Institutes of Health Clinical Center (CC), National Cancer Institute (NCI) | Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific | | 06/04 | | |
NCT00057980: Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma |
|
|
| Completed | 1/2 | 8 | US | celecoxib, epirubicin hydrochloride | Northwestern University, National Cancer Institute (NCI) | Liver Cancer | 02/07 | 02/07 | | |